National and Kapodistrian University of Athens
Σημασία των επιπέδων των ενεργοποιημένων αποπτωτικών κασπασών ορού σε ασθενείς με HBeAg αρνητική χρόνια ηπατίτιδα Β με ή χωρίς θεραπεία
Abstract
dc:descriptionBackground/Aim: The significance of the apoptotic caspase-generated K-18 fragment levels in HBeAg-negative chronic HBV infection and the effect of CHB treatment on hepatocyte apoptosis has not been evaluated. We investigated the association of K-18 fragment levels with the severity of liver injury and the changes in serum levels of the apoptotic caspase-generated fragments of K-18 in HBeAg-negative CHB patients under nucleos(t)ide analogue(s). Methods: We included 115 treatment-naive consecutive chronic HBV patients. 46 patients with CHB received lamivudine or adefovir monotherapy for ≥12 months. Of the 42 lamivudine treated patients, 23 developed virological breakthroughs and received add-on adefovir therapy for ≥12 months. Levels of K-18 fragments (U/L) were measured blindly in stored serum samples using the M30-Apoptosense ELISA Kit. All patients with CHB were submitted to a pre-treatment liver biopsy. Results: K-18 fragment levels were significantly lower in 53 inactive carriers than in 62 CHB patients (P<0.001). The receiver operating characteristic curve showed excellent diagnostic accuracy (c-statistic: 0.87) for differentiating inactive carriers from CHB patients. In the later group, serum levels of K-18 fragment correlated positively with ALT (r=0.54, P<0.001), AST (r=0.50, P<0.001), viraemia (r=0.42, P=0.026) and grading score (r=0.43, P<0.001) but not with fibrosis or steatosis (P>0.05). During initial therapy, the median serum K-18 fragment levels were significantly reduced from baseline [280 (149-2461)] to 6 months [164 (110-454), P<0.001)] and from 6 to 12 months [145 (113-280), P=0.031]. K-18 fragment levels increased at breakthroughs [187 (137-1063] compared to last previous visits [145 (118-389), P=0.015] but remained lower than baseline (P=0.036). Changes of K-18 fragment levels correlated positively with changes of ALT, AST and HBV DNA from baseline to 6 or 12 months of initial therapy. In patients with breakthroughs, K-18 fragment levels had only a trend for decline from adefovir addition mainly to 12 months [198 (124-1219) vs 156 (122-878), P=0.055]. Conclusions: Serum levels of K-18 fragments are strongly associated with the presence of liver injury in patients with HBeAg-negative chronic HBV infection and they seem to be a very useful marker for the differentiation between the inactive HBV carrier state and HBeAg-negative CHB. Serum levels of K-18 fragments decrease significantly during oral antiviral therapy in HBeAg-negative CHB in parallel with the improvements in ALT, AST and HBV-DNA levels. They increase again during breakthroughs and improve after an effective rescue therapy perhaps at a slower rate compared to the initial therapy.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Giannousis, Ioannis
- Γιαννούσης, Ιωάννης
Subjects
dc:subject × 21- Απόπτωση
- Κασπάσες
- Ηπατίτιδα B (HBV), Χρόνια
- Αντιική θεραπεία
- Κυττοκερατίνη 18
- Λαμιβουδίνη
- Αντεφοβίρη
- Apoptosis
- Caspase
- Chronic hepatitis B
- Antiviral therapy
- Keratin 18
- HBV
- Laminoudine
- Adefovir
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Clinical Medicine
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27300